AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
An Observational Study to Assess the Prevalence of Heart Failure in Type 2 Diabetes Patients
Completed
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 621
- Registration Number
- NCT04072523
- Locations
- 🇮🇳
Research Site, Delhi, India
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT04055168
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
Phase 3
Active, not recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Biological: Placebo
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2025-04-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 689
- Registration Number
- NCT04053634
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer
Completed
- Conditions
- Urologic Neoplasms
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2021-03-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 152
- Registration Number
- NCT04052113
- Locations
- 🇯🇵
Research Site, Kyoto-shi, Japan
Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma
Phase 3
Completed
- Conditions
- Severe Asthma
- First Posted Date
- 2019-08-07
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 65
- Registration Number
- NCT04048343
- Locations
- 🇯🇵
Research Site, Shinjuku-ku, Japan
Tezepelumab COPD Exacerbation Study
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Other: Placebo
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 337
- Registration Number
- NCT04039113
- Locations
- 🇬🇧
Research Site, Wakefield, United Kingdom
A Study on Patients With Chronic Kidney Disease (CKD) to Assess Treatment Experience and Patterns, Effect of the Treatment, Patient Outcomes and Patient Quality of Life
Completed
- Conditions
- Chronic Kidney Disease
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1052
- Registration Number
- NCT04034992
- Locations
- 🇬🇧
Research Site, Leeds,, Yorkshire, United Kingdom
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
Phase 3
Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 587
- Registration Number
- NCT04035486
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)
Completed
- Conditions
- Lung Cancer
- Interventions
- Other: Non Interventional
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 896
- Registration Number
- NCT04031898
- Locations
- 🇧🇬
Research Site, Wien, Bulgaria
A Study to Assess the Relative Bioavailability of 3 Different Formulations Under Fasted and Fed Condition
Phase 1
Completed
- Conditions
- Chronic Kidney Disease
- Interventions
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 25
- Registration Number
- NCT04024501
- Locations
- 🇩🇪
Research Site, Berlin, Germany
© Copyright 2025. All Rights Reserved by MedPath